Carcinoma, Renal Cell
Conditions
Keywords
renal cancer, tumor biomarker
Brief summary
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.
Interventions
OTHERBlood test
About 4 ml of blood draw
Sponsors
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers 2. Age ≥ 18 years old and able to provide written informed consent; 3. Have not received any systemic or topical treatment for kidney/liver tumors. 4. Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements.
Exclusion criteria
1. The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc. 2. The subjects is known or suspected of other malignancies. 3. There has been another history of malignancy in the past 5 years. 4. Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| NMAP level study | September 2019-September 2021 | To observe the difference in the expression level of nicotinamide metabolism related protein (NMAP) in the serum of newly diagnosed renal cancer and non-renal cancer patients. Draw the NMAP ROC curve and establish the appropriate Cut-off value to analyze its sensitivity and specificity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| NMAP plus other tumor biomarkers study | September 2019-September 2021 | According to NMAP and combined with other tumor biomarkers data such as AFP, multiple regression analysis was used to map the ROC curve and establish the appropriate Cut-off value to determine whether it is capable of distinguishing kidney cancer and liver cancer. |
Countries
China
Contacts
CONTACTMin NA Shi, MD
Outcome results
None listed